Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K(ATP) Channel

PURPOSE: Romidepsin is a histone deacetylase inhibitor (HDI) approved for the treatment of both cutaneous and peripheral T-cell lymphoma (CTCL and PTCL). During development, a thorough assessment of cardiac toxicity was conducted. EXPERIMENTAL DESIGN: A phase II single-agent nonrandomized study of r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Noonan, Anne M., Eisch, Robin A., Liewehr, David J., Sissung, Tristan M., Venzon, David J., Flagg, Thomas P., Haigney, Mark C., Steinberg, Seth M., Figg, William D., Piekarz, Richard L., Bates, Susan E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448401/
https://ncbi.nlm.nih.gov/pubmed/23589175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0109
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados